222 related articles for article (PubMed ID: 36869047)
1. ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors.
Mainwaring OJ; Weishaupt H; Zhao M; Rosén G; Borgenvik A; Breinschmid L; Verbaan AD; Richardson S; Thompson D; Clifford SC; Hill RM; Annusver K; Sundström A; Holmberg KO; Kasper M; Hutter S; Swartling FJ
Nat Commun; 2023 Mar; 14(1):1221. PubMed ID: 36869047
[TBL] [Abstract][Full Text] [Related]
2. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
[TBL] [Abstract][Full Text] [Related]
3. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.
Hill RM; Kuijper S; Lindsey JC; Petrie K; Schwalbe EC; Barker K; Boult JK; Williamson D; Ahmad Z; Hallsworth A; Ryan SL; Poon E; Robinson SP; Ruddle R; Raynaud FI; Howell L; Kwok C; Joshi A; Nicholson SL; Crosier S; Ellison DW; Wharton SB; Robson K; Michalski A; Hargrave D; Jacques TS; Pizer B; Bailey S; Swartling FJ; Weiss WA; Chesler L; Clifford SC
Cancer Cell; 2015 Jan; 27(1):72-84. PubMed ID: 25533335
[TBL] [Abstract][Full Text] [Related]
4. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
[TBL] [Abstract][Full Text] [Related]
5. Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma.
Borgenvik A; Holmberg KO; Bolin S; Zhao M; Savov V; Rosén G; Hutter S; Garancher A; Rahmanto AS; Bergström T; Olsen TK; Mainwaring OJ; Sattanino D; Verbaan AD; Rusert JM; Sundström A; Bravo MB; Dang Y; Wenz AS; Richardson S; Fotaki G; Hill RM; Dubuc AM; Kalushkova A; Remke M; Čančer M; Jernberg-Wiklund H; Giraud G; Chen X; Taylor MD; Sangfelt O; Clifford SC; Schüller U; Wechsler-Reya RJ; Weishaupt H; Swartling FJ
Cancer Res; 2022 Dec; 82(24):4586-4603. PubMed ID: 36219398
[TBL] [Abstract][Full Text] [Related]
6. Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability.
Luo Z; Xin D; Liao Y; Berry K; Ogurek S; Zhang F; Zhang L; Zhao C; Rao R; Dong X; Li H; Yu J; Lin Y; Huang G; Xu L; Xin M; Nishinakamura R; Yu J; Kool M; Pfister SM; Roussel MF; Zhou W; Weiss WA; Andreassen P; Lu QR
Nat Commun; 2023 Feb; 14(1):762. PubMed ID: 36765089
[TBL] [Abstract][Full Text] [Related]
7. BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma.
Shackleford GM; Shi XH; Swanson KS; Mahdi MY; Gonzalez-Gomez I; Asgharzadeh S; D'Apuzzo M; Erdreich-Epstein A; Moats RA
PLoS One; 2016; 11(6):e0156907. PubMed ID: 27310018
[TBL] [Abstract][Full Text] [Related]
8. α5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth.
Sengupta S; Weeraratne SD; Sun H; Phallen J; Rallapalli SK; Teider N; Kosaras B; Amani V; Pierre-Francois J; Tang Y; Nguyen B; Yu F; Schubert S; Balansay B; Mathios D; Lechpammer M; Archer TC; Tran P; Reimer RJ; Cook JM; Lim M; Jensen FE; Pomeroy SL; Cho YJ
Acta Neuropathol; 2014 Apr; 127(4):593-603. PubMed ID: 24196163
[TBL] [Abstract][Full Text] [Related]
9. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
Park AK; Lee SJ; Phi JH; Wang KC; Kim DG; Cho BK; Haberler C; Fattet S; Dufour C; Puget S; Sainte-Rose C; Bourdeaut F; Grill J; Delattre O; Kim SK; Park WY
Neuro Oncol; 2012 Feb; 14(2):203-14. PubMed ID: 22090452
[TBL] [Abstract][Full Text] [Related]
10. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.
Northcott PA; Fernandez-L A; Hagan JP; Ellison DW; Grajkowska W; Gillespie Y; Grundy R; Van Meter T; Rutka JT; Croce CM; Kenney AM; Taylor MD
Cancer Res; 2009 Apr; 69(8):3249-55. PubMed ID: 19351822
[TBL] [Abstract][Full Text] [Related]
11. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of genomic aberrations during clinical progression of medulloblastoma.
Korshunov A; Benner A; Remke M; Lichter P; von Deimling A; Pfister S
Acta Neuropathol; 2008 Oct; 116(4):383-90. PubMed ID: 18704466
[TBL] [Abstract][Full Text] [Related]
13. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
[TBL] [Abstract][Full Text] [Related]
14. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.
Swartling FJ; Savov V; Persson AI; Chen J; Hackett CS; Northcott PA; Grimmer MR; Lau J; Chesler L; Perry A; Phillips JJ; Taylor MD; Weiss WA
Cancer Cell; 2012 May; 21(5):601-613. PubMed ID: 22624711
[TBL] [Abstract][Full Text] [Related]
15. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
16. Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc.
Kim HS; Woolard K; Lai C; Bauer PO; Maric D; Song H; Li A; Kotliarova S; Zhang W; Fine HA
Cancer Res; 2012 Nov; 72(22):6065-75. PubMed ID: 22986743
[TBL] [Abstract][Full Text] [Related]
17. An animal model of MYC-driven medulloblastoma.
Pei Y; Moore CE; Wang J; Tewari AK; Eroshkin A; Cho YJ; Witt H; Korshunov A; Read TA; Sun JL; Schmitt EM; Miller CR; Buckley AF; McLendon RE; Westbrook TF; Northcott PA; Taylor MD; Pfister SM; Febbo PG; Wechsler-Reya RJ
Cancer Cell; 2012 Feb; 21(2):155-67. PubMed ID: 22340590
[TBL] [Abstract][Full Text] [Related]
18. Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma.
Ahmad Z; Jasnos L; Gil V; Howell L; Hallsworth A; Petrie K; Sawado T; Chesler L
PLoS One; 2015; 10(3):e0119834. PubMed ID: 25785590
[TBL] [Abstract][Full Text] [Related]
19. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
[TBL] [Abstract][Full Text] [Related]
20. A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.
Di Giulio S; Colicchia V; Pastorino F; Pedretti F; Fabretti F; Nicolis di Robilant V; Ramponi V; Scafetta G; Moretti M; Licursi V; Belardinilli F; Peruzzi G; Infante P; Goffredo BM; Coppa A; Canettieri G; Bartolazzi A; Ponzoni M; Giannini G; Petroni M
Oncogene; 2021 Oct; 40(43):6143-6152. PubMed ID: 34508175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
